Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).

Prevention of breast cancer: current state of the science and future opportunities.

Overview of resistance to systemic therapy in patients with breast cancer.

New approaches to reverse resistance to hormonal therapy in human breast cancer.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?

Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?

Prevention of breast cancer using SERMs and aromatase inhibitors.

Inhibition of aromatase: insights from recent studies.

Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.

Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.

Chemoprevention with aromatase inhibitors--trial strategies.

Selecting adjuvant endocrine therapy for breast cancer.

[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment]

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.

Role of antiestrogens and aromatase inhibitors in breast cancer treatment.

The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.

Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

Challenges in the endocrine management of breast cancer.

Aromatase inhibitors and breast cancer.